Rosuvastatin/valsartan - LG Chem

Drug Profile

Rosuvastatin/valsartan - LG Chem

Alternative Names: Rovatitan; Valsartan/rosuvastatin; VR

Latest Information Update: 17 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator LG Life Sciences
  • Developer LG Chem; Merck Ltd. Korea
  • Class Antihyperlipidaemics; Antihypertensives; Branched-chain amino acids; Fluorobenzenes; Pyrimidines; Small molecules; Sulfonamides; Tetrazoles
  • Mechanism of Action Angiotensin type 1 receptor antagonists; HMG-CoA reductase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Hyperlipidaemia; Hypertension

Most Recent Events

  • 31 Mar 2013 LG Life Sciences completes a phase III trial in Hypertension & hyperlipidaemia in South Korea (NCT01918332)
  • 31 Jan 2013 LG Life Sciences completes a phase I bioequivalence trial for Hypertension & hyperlipidaemia (in volunteers) in South Korea (NCT01918358)
  • 31 Dec 2012 LG Life Sciences initiates enrolment in a phase I bioequivalence trial for Hypertension & hyperlipidaemia (in volunteers) in South Korea (NCT01918358)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top